89bio initiates phase 3 entrust trial of pegozafermin in patients with severe hypertriglyceridemia (shtg)

San francisco, may 23, 2023 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of entrust, a phase 3 trial evaluating the efficacy, safety and tolerability of pegozafermin in patients with severe hypertriglyceridemia (shtg). "we are pleased to initiate the entrust trial of pegozafermin in shtg, an important milestone for the company that demonstrates the rapid progress we have made since inception, and also signifies entry of the first fgf21 analog into phase 3 development,” said hank mansbach, chief medical officer of 89bio.
ETNB Ratings Summary
ETNB Quant Ranking